Literature DB >> 2492587

Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.

P Brandtzaeg1, P Kierulf, P Gaustad, A Skulberg, J N Bruun, S Halvorsen, E Sørensen.   

Abstract

We studied prospectively the quantitative relation of circulating endotoxin (lipooligosaccharides [LOSs]) and the development of multiple organ failure and death in 45 consecutively admitted patients with bacteriologically verified systemic meningococcal disease (SMD). A plasma LOS level of greater than 700 ng/L correlated with development of severe septic shock (P less than .0001), adult respiratory distress syndrome (P = .0035), a pathologically elevated serum creatinine level (P less than .0001), or death as a consequence of multiple organ failure (P = .0002). Initial plasma LOS levels of less than 25, 25-700, 700-10,000, and greater than 10,000 ng/L were associated with 0%, 14%, 27%, and 86% fatality, respectively. The LOS half-life after initiation of antibiotic therapy was 1-3 h. Increasing plasma LOS levels were never seen. These observations suggest that LOS quantitation using the limulus amebocyte lysate assay with a chromogenic substrate gives important progsnotic information and may provide new insight concerning pathophysiological aspects of SMD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492587     DOI: 10.1093/infdis/159.2.195

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  122 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 2.  Pathophysiology of meningococcal meningitis and septicaemia.

Authors:  N Pathan; S N Faust; M Levin
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

3.  Reducing mortality from meningococcal disease.

Authors:  N Begg
Journal:  BMJ       Date:  1992-07-18

Review 4.  The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-11-08       Impact factor: 1.568

5.  Cytoskeletal alterations in lipopolysaccharide-induced bovine vascular endothelial cell injury and its prevention by sodium arsenite.

Authors:  D Chakravortty; N Koide; Y Kato; T Sugiyama; M Kawai; M Fukada; T Yoshida; T Yokochi
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

6.  Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway.

Authors:  Susu M Zughaier; Yih-Ling Tzeng; Shanta M Zimmer; Anup Datta; Russell W Carlson; David S Stephens
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Authors:  H Jin; R Yang; S Marsters; A Ashkenazi; S Bunting; M N Marra; R W Scott; J B Baker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Endotoxin release and cytokine production in acute and chronic meningococcaemia.

Authors:  J M Prins; F N Lauw; B H Derkx; P Speelman; E J Kuijper; J Dankert; S J van Deventer
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Lipopolysaccharides up-regulate Kir6.1/SUR2B channel expression and enhance vascular KATP channel activity via NF-kappaB-dependent signaling.

Authors:  Weiwei Shi; Ningren Cui; Zhongying Wu; Yang Yang; Shuang Zhang; Hongyu Gai; Daling Zhu; Chun Jiang
Journal:  J Biol Chem       Date:  2009-12-03       Impact factor: 5.157

10.  Ability of gonococcal and meningococcal lipooligosaccharides to clot Limulus amebocyte lysate.

Authors:  R I Roth; R Yamasaki; R E Mandrell; J M Griffiss
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.